Aspire Biopharma Holdings (ASBP) Notes Payables (2021 - 2025)

Aspire Biopharma Holdings (ASBP) has reported Notes Payables for 4 consecutive years, with $40954.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Notes Payables fell 96.77% year-over-year to $40954.0 in Q4 2025; TTM through Dec 2025 was $40954.0, a 96.77% decrease from a year earlier, with the FY2025 full-year figure at $40954.0, down 96.77% from the prior year.
• Notes Payables was $40954.0 for Q4 2025 at Aspire Biopharma Holdings, down from $3.6 million in the prior quarter.
• Over five years, Notes Payables peaked at $3.6 million in Q3 2025 and troughed at $12384.0 in Q4 2023.
• A 4-year average of $873703.7 and a median of $432036.0 in 2024 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables jumped 10129.59% in 2024 and slumped 96.77% in 2025, its largest moves.
• Over 4 years, Notes Payables stood at $238596.0 in 2021, then plunged by 94.81% to $12384.0 in 2023, then jumped by 10129.59% to $1.3 million in 2024, then tumbled by 96.77% to $40954.0 in 2025.
• The last three Notes Payables figures came in at $40954.0 (Q4 2025), $3.6 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.